The Sanford Community Cancer Program (SCCP) remains committed to its original goals and aims as stated in our 2013 application. The SCCP continues to increase patient participation in cancer control, prevention, care delivery, treatment, and imaging studies across its expanding network. The rural communities of the upper Midwest and Central Plains represent a large underserved population for cancer treatment, care delivery and clinical trials (PMID:24097196 PMID:22046848 PMID:19621978). The reasons for this disparity are multi- factorial but a main obstacle is access to services in rural regional areas. Sanford Health has developed a network of hospitals, cancer centers and clinics to provide high-quality, multi-disciplinary cancer treatment, clinical trials, and cancer care delivery to this underserved area. Sanford Health has designated cancer care as a Center of Excellence; elevating cancer care as a top priority to the patients it serves. The SCCP has expanded from five to seven components in the past five years, adding two new components to improve trial access in rural and underserved areas. It is hypothesized that this disparity in care for this rural population can be improved by utilizing the organized SCCP network community. This proposal describes how the NCI Community Oncology Research Program (NCORP) partnership will help deliver clinical care and offer clinical trials across the rural area served by the SCCP. This will be accomplished through the following aims: 1. Maintain and enhance robust accrual to NCI Division of Cancer Prevention (DCP) supported clinical trials through seven components. 2. Address disparities in clinical trial accrual in underserved and underrepresented populations to increase participation. 3. Cultivate innovative access points to address barriers to clinical trial accrual through outreach and telemedicine. 4. Expand Cancer Care Delivery Research infrastructure. Through these four aims the Sanford Community Cancer Program will continue to offer NCI clinical trials and provide state-of-the-art cancer treatment and cancer care delivery to millions of people across six states in rural America. The SCCP's ability to provide clinical trials through outreach and telemedicine to this underserved rural population of patients increases their opportunity for participation in a trial as a treatment option. Telemedicine services are currently provided in existing Sanford Clinics in rural communities to deliver oncology consultations, surveillance exams and chemotherapy oversight. As a community based health care organization, the SCCP will participate in the development and implementation of cancer care delivery research to better understand and improve patient outcomes. The SCCP will design and develop additional community based investigator-initiated Cancer Care Delivery pilot projects with the goal to collaborate with the SCCP's primary Research Bases.

Public Health Relevance

The Sanford Community Cancer Program (SCCP) covers rural communities of the upper Midwest and Central Plains representing a large underserved population for cancer treatment, care delivery and clinical trials. The NCI Community Oncology Research Program (NCORP) partnership will help deliver clinical care and offer clinical trials across the rural area served by the SCCP. This will be accomplished through the following aims: maintain and enhance robust accrual to NCI Division of Cancer Prevention (DCP) supported clinical trials through seven components; address disparities in clinical trial accrual in underserved and underrepresented populations to increase participation; cultivate innovative access points to address barriers to clinical trial accrual through outreach and telemedicine; expand current personnel and infrastructure, and contribute to Cancer Care Delivery Research trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189825-06
Application #
9773473
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Good, Marge
Project Start
2014-08-12
Project End
2025-07-31
Budget Start
2019-08-12
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sanford Research/Usd
Department
Type
DUNS #
050113252
City
Sioux Falls
State
SD
Country
United States
Zip Code
57104
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32

Showing the most recent 10 out of 11 publications